OBJECTIVES: Therapy of non-small cell lung cancer is a very complex clinical problem. Revealing of an optimum version of therapy requires not only the analysis of data by clinical efficiency, but also assessments of efficiency of expenses for applied medical products.  Objective of research was an assessment the efficiency of expenses of Gefitinibum in patients with non-small cell lung cancer as a second line therapy.  METHODS: Modelling was made on the basis of results of clinical researches INTEREST. We considered only direct medical costs. Expenses for correction of the side effects cased hospitalization were counted on  tariffs Compulsory Medical Service  in St. Petersburg, 2013. Costs of compared medicines (Docetaxelum, Pemetrexed) were received from results of auctions for 01.08.2012-01.06.2013  (a database "Cursor").  RESULTS: Data of the research had shown that in case of an inefficiency of chemotherapy of the first line therapy, Gefitinibum increased life expectancy in view of it's quality on 0,013 QALY and provide savings the 276 USD for 1 patient in comparison with original Docetaxelum. Costs for 1 month without progressing were 2 813 and 2 703 USD for Docetaxelum and Gefitinibum, respectively. Costs of 1 treatment course (21 days) of Pemetrexed were in 1,9 times higher than Gefitinibum. Therapy with Gefitinibum increase of life expectancy on 6 months and on 0,226 QALY in comparison with Pemetrexed. Costs of 1 month without progression for Gefitinib were in average 1,8 times less (2 699 and 5 016 USD for Gefitinib and Pemetrexed, respectively). Therapy with Gifinitib allows to decrease the direct medical costs on 19%. CONCLUSIONS:  Therapy with Gifinitib as the second line therapy in patients with non-small cell lung cancer is effective from clinical and economical point of view.